Not for human consumption.

Not for human consumption. Amid the FDA’s efforts to regulate peptides, communities on platforms like Telegram are conducting their own lab testing and trials, often without clinical backing. Retatrutide, a new frontrunner in weight loss drugs, shows promise with “28.7% weight loss in Phase 3 trials,” yet the market for grey-market peptides like BPC-157 continues to blur lines between legitimate health intervention and regulatory overstep. ~ learn more